Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878584 | 0.93 | — | — | |
| SCHEMBL12467506 | 0.86 | ALDH1A1 (0.34) | MAOAMAOBALDH1A1 | |
| SCHEMBL7783727 | 0.86 | ALDH1A1 (0.39) | MAOAMAOBALDH1A1 | |
| SCHEMBL1524983 | 0.86 | ALDH1A1 (0.39) | MAOAMAOBALDH1A1 | |
| SCHEMBL2540038 | 0.84 | ALDH1A1 (0.36) | MAOAMAOBALDH1A1 | |
| SCHEMBL166697 | 0.83 | — | — | |
| SCHEMBL12465603 | 0.82 | ALDH1A1 (0.34) | MAOAMAOBALDH1A1 | |
| SCHEMBL1524597 | 0.81 | — | — | |
| SCHEMBL19463253 | 0.75 | — | — | |
| SCHEMBL5066474 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
| EP-3099738-B1 | POLYOLEFIN COPOLYMERS AS COLOUR IMPROVERS IN POLYAMIDES | BASF SE (DE) | 2017-11-29 | — | — | EP | disclosed |
| EP-3233880-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| EP-3099738-A1 | POLYOLEFIN COPOLYMERS AS COLOR ENHANCERS IN POLYAMIDES | BASF SE (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-20160340509-A1 | Polyolefin Copolymers as Color Enhancers in Polyamides | BASF SE (DE) | 2016-11-24 | — | — | US | disclosed |
| WO-2016098028-A1 | END CAPPED NUCLEIC ACID MOLECULES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-7220810-B2 | Polymer film and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7217830-B2 | Organic silicon compound and method for preparing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-15 | — | — | US | disclosed |
| WO-2006137840-A2 | DIPHENYL ETHER ANTIMICROBIAL COMPOUNDS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060041025-A1 | 5-Alkyl (4-26 carbon atoms)-2-phenoxyphenols; enoyl reductase enzyme inhibitor; drug resistance; side-effect reduction; nicrobiocides; carriers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | disclosed |
| US-20060009600-A1 | Polymer film and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20060004219-A1 | Organic silicon compound and method for preparing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| US-6703182-B1 | PHOTOPOLYMERISABLE COMPOSITIONS COMPRISING SAID COMPOUNDS AND USE OF THE COMPOUNDS AS LATENT ACIDS, WHICH CAN BE ACTIVATED BY IRRADIATION WITH LIGHT | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-03-09 | — | — | US | disclosed |
| EP-1105373-B1 | UNSATURATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SC HOLDING AG (CH) | 2002-10-09 | — | — | EP | disclosed |
| EP-1105373-A1 | UNSATURATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000010972-A1 | NEW UNSATURATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | MAOA 4538/4885MAOB 4654/4885ALDH1A1 3871/4885 |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | MAOA 4538/4885MAOB 4654/4885ALDH1A1 3871/4885 |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NSUN2, NSUN3, RNGTT | MAOA 4649/4885MAOB 4757/4885ALDH1A1 4255/4885 |
| US-20060004219-A1 | Organic silicon compound and method for preparing the same | AR, PKD1, SKP2 | MAOA 2556/4885MAOB 2266/4885ALDH1A1 1352/4885 |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | MAOA 4367/4885MAOB 4587/4885ALDH1A1 3685/4885 |
| US-20060041025-A1 | 5-Alkyl (4-26 carbon atoms)-2-phenoxyphenols; enoyl reductase enzyme inhibitor; drug resistance; side-effect reduction; nicrobiocides; carriers | CBR1, CBR3, FAR1 | MAOA 290/4885MAOB 156/4885ALDH1A1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.